These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 18049099

  • 1. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, Perera A, Peña Y, Hernández A, Sanchez Y, Romero S, Leyva R, Prats A, Fernandez R.
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 3. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 4. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 5. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
    Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR.
    J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
    [Abstract] [Full Text] [Related]

  • 6. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

  • 7. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J, Glatting G, Seitz U, Rentschler M, Neumaier B, Bunjes D, Duncker C, Dohr D, Bergmann L, Reske SN.
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [Abstract] [Full Text] [Related]

  • 9. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [Abstract] [Full Text] [Related]

  • 10. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 01; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans.
    Lahorte CM, van de Wiele C, Bacher K, van den Bossche B, Thierens H, van Belle S, Slegers G, Dierckx RA.
    Nucl Med Commun; 2003 Aug 01; 24(8):871-80. PubMed ID: 12869819
    [Abstract] [Full Text] [Related]

  • 12. 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation.
    Virta JR, Tolvanen T, Någren K, Brück A, Roivainen A, Rinne JO.
    J Nucl Med; 2008 Mar 01; 49(3):347-53. PubMed ID: 18287260
    [Abstract] [Full Text] [Related]

  • 13. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
    Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, Steinmetz ND, Vanderheyden JL, Green AM, Verbeke K.
    J Nucl Med; 2003 Jun 01; 44(6):947-52. PubMed ID: 12791824
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [Abstract] [Full Text] [Related]

  • 15. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 01; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 16. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW, Bijster M, Krenning EP, De Jong M.
    J Nucl Med; 2004 Jul 01; 45(7):1260-9. PubMed ID: 15235075
    [Abstract] [Full Text] [Related]

  • 17. Biodistribution and radiation dosimetry of [123I]ADAM in healthy human subjects: preliminary results.
    Kauppinen TA, Bergström KA, Heikman P, Hiltunen J, Ahonen AK.
    Eur J Nucl Med Mol Imaging; 2003 Jan 01; 30(1):132-6. PubMed ID: 12483421
    [Abstract] [Full Text] [Related]

  • 18. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F.
    J Nucl Med; 2005 Jan 01; 46(1):60-6. PubMed ID: 15632035
    [Abstract] [Full Text] [Related]

  • 19. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Mar 01; 46(3):464-71. PubMed ID: 15750160
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models.
    Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP.
    J Nucl Med; 2005 Jan 01; 46(1):121-9. PubMed ID: 15632042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.